GlyNAC

GlyNAC is a defined equimolar combination of glycine and N-acetylcysteine (NAC) that supplies the two amino acid precursors whose availability limits the intracellular biosynthesis of glutathione (gamma-glutamylcysteinylglycine, GSH), the most abundant endogenous non-protein thiol antioxidant in mammalian cells. The combination was developed and systematically investigated by Rajagopal V. Sekhar and colleagues at Baylor College of Medicine beginning approximately 2018, on the basis of prior observations that aging, HIV infection, and type 2 diabetes are associated with deficient intracellular glutathione concentrations traceable to diminished availability of both glycine and cysteine rather than to reduced activity of the synthetic enzymes glutamate-cysteine ligase and glutathione synthetase. The mechanistic rationale is that NAC undergoes deacetylation to cysteine in the intestinal mucosa and liver, while supplemental glycine directly enters the glutathione synthetic pathway; co-administration of both precursors at physiologically relevant doses corrects the dual substrate deficit and restores intracellular glutathione concentrations within two weeks in human subjects, with downstream improvements in oxidative stress biomarkers, mitochondrial fatty-acid oxidation, inflammation, insulin resistance, endothelial function, genomic integrity, and cellular senescence markers.

The principal clinical evidence derives from a series of trials conducted at Baylor College of Medicine. A 36-week open-label pilot trial in older adults (aged 61 to 80 years) demonstrated that 24 weeks of GlyNAC supplementation at approximately 100 milligrams per kilogram in the published literature of each component (approximately 7 grams of glycine and 7 grams of NAC daily for a 70-kilogram adult) corrected red blood cell glutathione deficiency, reduced plasma markers of oxidative stress (thiobarbituric acid reactive substances, F2-isoprostanes), improved mitochondrial fatty-acid oxidation by indirect calorimetry, lowered fasting insulin resistance (homeostatic model assessment of insulin resistance), improved grip strength and gait speed, and improved cognitive scores on the Montreal Cognitive Assessment; benefits receded within 12 weeks of supplementation withdrawal. A subsequent double-blind, placebo-controlled randomized clinical trial in 24 older adults (aged 65 to 80 years) confirmed these findings over 16 weeks of supplementation, with additional demonstration of improvements in multiple hallmarks of aging including mitochondrial dysfunction, impaired mitophagy, inflammation, endothelial dysfunction, genomic damage, stem cell fatigue, and cellular senescence. An independent dose-finding randomized controlled trial conducted by the Nestle Institute of Health Sciences in 114 healthy older adults tested three dose tiers (2.4, 4.8, and 7.2 grams in the published literature total in a 1:1 glycine-to-NAC ratio) over two weeks and confirmed dose-dependent increases in plasma glycine and cysteine concentrations and in erythrocyte glutathione.

Parallel investigations have extended the GlyNAC evidence base to HIV-infected adults (open-label, improvements in oxidative stress, mitochondrial function, inflammation, endothelial function, insulin resistance, strength, and cognition), type 2 diabetes (pilot study, 30 percent improvement in mitochondrial fatty-acid oxidation and 22 percent reduction in insulin resistance over 14 days), and COVID-19 (observational characterization of severe glutathione deficiency and oxidative stress in hospitalized patients). A preclinical mouse lifespan study demonstrated that GlyNAC supplementation initiated at 65 weeks of age (corresponding to late middle age in humans) extended median lifespan by 24 percent and corrected glutathione deficiency, oxidative stress, mitochondrial dysfunction, impaired mitophagy, abnormal nutrient sensing, and genomic damage in liver, heart, and kidney tissues.

The combination is well tolerated in all published trials. No serious adverse events attributable to GlyNAC have been reported. The principal mild adverse events are gastrointestinal (nausea, bloating), attributable to the NAC component, and are dose-dependent and generally self-limiting. The glycine component has an extensive safety record as a dietary amino acid and as a research compound at doses up to 60 grams in the published literature in schizophrenia trials. NAC has an established clinical safety profile as a mucolytic and acetaminophen-overdose antidote at doses substantially exceeding those used in GlyNAC research.

This monograph documents the composition, molecular pharmacology, and glutathione biosynthetic rationale of GlyNAC; the pharmacokinetics of the individual components; the complete preclinical and clinical evidence base across aging, HIV, diabetes, and COVID-19 indications; sourcing and quality verification; reconstitution and handling; stack interactions; the adverse-event profile; and a comparative assessment of five alternative glutathione-replenishing strategies (N-acetylcysteine alone, oral reduced glutathione, liposomal glutathione, alpha-lipoic acid, and whey protein concentrate) against GlyNAC on five competency standards (mechanistic completeness, effect size, clinical validation, side-effect profile, and practical accessibility).